Clinical Trials

Inclusion Criteria:

• Stage IIIB or IV NSCLC (any histology) at the time of study entry
• Histologically or cytologically confirmed diagnosis of NSCLC that is:
  1. EGFR wt as per patient standard of care by a validated test
  2. AND ALK-negative rearrangement as part of the patient standard of care by a validated test
  3. AND (by central assessment) either:
     • Cohort 1: Pre-treated patients with cMET GCN ≥ 6 or
     • Cohort 2: Pre-treated patients with cMET GCN ≥4 and < 6, or
     • Cohort 3: Pre-treated patients with cMET GCN < 4, or
     • Cohort 4: Pre-treated patients with cMET mutations regardless of cMET GCN, or
     • Cohort 5: Treatment-naïve patients with cMET dysregulation
     • Cohort 6: Pre-treated patients with either cMET GCN ≥ 10 without cMET mutations or cMET mutations regardless of cMET GCN
• To be eligible for Cohorts 1-4, patients must have failed one or two prior lines of systemic therapy for advanced/metastatic disease
• To be eligible for Cohort 6, patients must have failed one prior line of systemic therapy for advanced/metastatic disease
• To be eligible for Cohort 5, patients must not have received any systemic therapy for advanced/metastatic disease
• At least one measurable lesion as defined by RECIST 1.1
• Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study.
• Patients must have adequate organ function
• ECOG performance status (PS) of 0 or 1 Details and other protocol-defined inclusion criteria may apply

Exclusion Criteria:

• Prior treatment with crizotinib, or any other cMET or HGF inhibitor
• Patients with characterized EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 mutations
• Patients with characterized ALK-positive rearrangement
• Clinically significant, uncontrolled heart diseases.
• Patients receiving treatment with medications that cannot be discontinued at least 1 week prior to first INC280 treatment and for the duration of the study:
  • Strong inducers of CYP3A4
• Impairment of GI function or GI disease that may significantly alter the absorption of INC280
• Patients receiving treatment with any enzyme-inducing anticonvulsant
• Applicable to Cohorts 1-4 only: Previous anti-cancer and investigational agents within 4 weeks or ≤ 5 x half-life of the agent (whichever is longer) before first dose
• Pregnant or nursing women
• Women of child-bearing potential, unless they are using highly effective methods of contraception
• Sexually active males unless they use a condom during intercourse
• Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis